July 27, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Files Composition of Matter Patent Application on NR2F6 Modulating Small Molecules
July 13, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma President Harry Lander Provides Mid-year Update on Company’s Progress and Developments
June 30, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company
June 16, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc.’s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Programy
June 7, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Retains Objective Capital Partners, LLC to Explore Non-Dilutive Funding Opportunities
May 24, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
May 19, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy. Company Initiates Preclinical Development of Cells Capable of Seeking and Destroying Cancer.
May 11, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
May 3, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients. Initial results from Pan Am Cancer Center suggest positive impact from HemaXellerate on bone marrow suppression with no toxicity
April 28, 2016 SOURCE: REGEN BIOPHARMA INC.
Regen BioPharma’s HemaXellerate Therapy for Treating Aplastic Anemia Licensed for Proof of Concept Study